Skip to content

BioCryst Pharmaceuticals BCRX Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
25M0.0%
ALN
Alnylam PharmaceuticalsALNY
5M0.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10M0.0%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
10M0.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's convertible preferred stock authorized shares?
BioCryst Pharmaceuticals (BCRX) reported convertible preferred stock authorized shares of 5M in Q1 2026.
How has BioCryst Pharmaceuticals's convertible preferred stock authorized shares changed year-over-year?
BioCryst Pharmaceuticals's convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 5M to 5M.
What is the long-term trend for BioCryst Pharmaceuticals's convertible preferred stock authorized shares?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 5M to 5M.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.